Neurology RTM: Migraine, MS, and Seizure Monitoring

Why Neurology Is an Underutilized RTM Specialty

Remote therapeutic monitoring has gained the most traction in cardiology and primary care because the physiologic monitoring use cases (blood pressure, weight) are intuitive and well-established. Neurology has been slower to adopt RTM, but the clinical case is equally — arguably more — compelling: migraine, multiple sclerosis, and epilepsy are conditions where between-visit symptom data is clinically critical, where patient-reported outcomes are the primary outcome measures, and where early symptom detection drives the most impactful clinical interventions.

The economic context for neurology RTM is significant. The average neurologist sees 15-20 established patients per day — a mix of migraine, epilepsy, MS, Parkinson's, neuropathy, and movement disorders. At current Medicare E/M rates (approximately $145-$210 for 99214-99215), a neurologist generating revenue only through office visits has a revenue ceiling constrained by appointment availability and patient access. RTM provides a monthly recurring revenue stream that does not require additional appointment slots — it operates between visits.

For patients, the benefit is equally compelling. A migraine patient who tracks headache frequency, severity, trigger patterns, and acute medication use through an RTM platform provides their neurologist with data that transforms a 4-appointment-per-year relationship into a continuous clinical management relationship. A patient whose headache diary reveals 15+ headache days per month (the threshold for chronic migraine per ICHD-3 criteria) triggers a treatment escalation that might not have been identified until the next quarterly visit.

This article covers the clinical design, billing mechanics, and revenue math for three neurological RTM programs: migraine monitoring, MS symptom monitoring, and seizure log tracking.

Migraine RTM: What to Monitor and Alert Thresholds

Migraine (ICD-10: G43.x) affects approximately 12-15% of the US population and is characterized by episodic attacks of moderate-to-severe headache with associated features (nausea, photophobia, phonophobia, aura). The clinical management of migraine depends critically on headache frequency data — the distinction between episodic migraine (under 15 headache days/month) and chronic migraine (15+ headache days/month, with ≥8 meeting migraine criteria) drives treatment class selection (acute only vs. preventive), triptan prescribing patterns, and biologics eligibility.

Migraine RTM monitoring parameters:

Headache days per month: Patient logs each headache day, rate severity 1-10, note presence or absence of migraine-associated features. Alert threshold: 12+ headache days in any 28-day window → provider review for chronic migraine diagnostic status and preventive therapy evaluation.

Acute medication use: Patient logs each dose of triptan, ergotamine, NSAID, or combination analgesic taken for acute headache. Alert threshold: >10 days of acute medication use in any 28-day window → medication overuse headache (MOH) screening. MOH is a major reversible cause of chronic daily headache and is identifiable through medication use tracking — making this one of the highest-yield RTM monitoring parameters in headache medicine.

Migraine severity (MIDAS equivalent tracking): Monthly assessment of disability — missed workdays, missed household activity days, partial productivity loss. Alert threshold: MIDAS score ≥21 (severe disability) on any monthly assessment → urgent treatment escalation discussion.

Aura frequency tracking: for patients with known migraine with aura, track aura frequency. New or increased aura frequency — especially in females on combined hormonal contraceptives — is a cerebrovascular risk signal requiring clinical evaluation.

Trigger identification: weekly questionnaire documenting suspected triggers (sleep disruption, hormonal cycle timing, weather changes, stress, dietary factors). Over 4-8 weeks, RTM platform generates a patient-specific trigger profile that informs behavioral counseling.

Preventive therapy response tracking: for patients on preventive therapy (topiramate, amitriptyline, propranolol, valproate, or CGRP monoclonal antibodies), monthly headache day count is the primary efficacy endpoint. The CGRP biologic response threshold is ≥50% reduction in monthly headache days — RTM data provides the objective basis for this assessment at each 3-month payer re-authorization.

Multiple Sclerosis RTM: Symptom Tracking and Relapse Detection

Multiple sclerosis (ICD-10: G35) is a chronic demyelinating disease with variable presentation — relapsing-remitting (RRMS), secondary progressive (SPMS), and primary progressive (PPMS). The clinical management of MS is increasingly defined by treat-to-target strategies where treatment decisions are driven by measurable disease activity indicators: MRI lesion burden, relapse frequency, and functional progression.

RTM in MS does not replace MRI monitoring (the gold standard for subclinical disease activity) but augments it by capturing patient-reported functional status and symptom changes that may indicate a relapse or progression between scheduled MRI appointments.

MS RTM monitoring parameters:

Fatigue scale (Fatigue Severity Scale, FSS): Weekly patient-rated fatigue assessment (FSS ≥36 = clinically significant fatigue, scale 9-63). Alert threshold: FSS increase of >10 points over 2 consecutive weeks → provider review for relapse, disease progression, or exacerbating factors (infection, heat exposure, depression).

Ambulatory function: Patient rates walking ability (can walk >200 meters, 100-200 meters, <100 meters, wheelchair-dependent). New functional category decline → alert to provider within 24 hours.

Visual symptoms: Patient reports any new blurring, double vision, or loss of visual acuity. Any new visual complaint → same-day provider notification (optic neuritis is a common MS relapse presentation and requires urgent evaluation).

Sensory symptoms: Numbness, tingling, or Lhermitte's sign (electric shock sensation with neck flexion — a specific MS demyelination sign). New sensory symptom onset → provider review within 48 hours.

Spasticity: Patient-rated spasticity (modified Ashworth scale equivalent, 0-4). Progressive spasticity increase may indicate functional worsening requiring rehabilitation or medication adjustment.

Medication adherence: for patients on oral disease-modifying therapies (fingolimod, siponimod, cladribine, dimethyl fumarate, teriflunomide), daily adherence tracking. For injectable DMTs (interferon beta, glatiramer acetate), injection log tracking. Alert threshold: >2 consecutive missed doses → MA outreach for barrier assessment.

Relapse identification protocol: when a patient reports new neurological symptoms lasting >24 hours that are not attributable to fever, infection, or metabolic cause, this is a candidate MS relapse. Protocol: provider review within 24 hours, determine if high-dose methylprednisolone (1 gram IV × 3-5 days) is appropriate, arrange urgent MRI if relapse confirmation is needed for treatment decision.

Seizure Log RTM: Epilepsy Between-Visit Monitoring

Epilepsy (ICD-10: G40.x) is characterized by recurrent unprovoked seizures, and seizure frequency and type are the primary metrics for treatment efficacy assessment. The traditional seizure tracking method — patient self-report at office visits — is notoriously unreliable: studies show that patients recall only 40-60% of seizures that actually occurred, and seizures occurring during sleep are frequently undetected without a bed partner's account.

RTM seizure log tracking improves on self-recall through daily structured seizure event logging — a brief questionnaire that prompts the patient (or caregiver) each evening to report whether a seizure occurred that day, its type and duration, postictal symptoms, and any potential triggers.

Seizure log RTM monitoring parameters:

Seizure frequency: Patient or caregiver logs each seizure event type (focal aware, focal impaired awareness, generalized tonic-clonic, absence, myoclonic, unknown). Alert threshold: any GTC seizure → provider notification same day; any seizure cluster (3+ events in 24 hours) → urgent provider notification.

Seizure duration: log duration of each event. Duration >5 minutes for a GTC seizure is a status epilepticus threshold — patient requires immediate emergency evaluation. Build an emergency instruction into the RTM platform that instructs caregivers to call 911 if the patient is in a seizure >5 minutes rather than submitting an RTM log entry.

Medication adherence: daily logging of each antiseizure medication (ASM) dose taken (levetiracetam, lamotrigine, valproate, carbamazepine, etc.). Alert threshold: >2 consecutive missed doses → urgent provider contact (ASM non-adherence is the most common cause of breakthrough seizures in controlled epilepsy).

Injury log: patient or caregiver notes any injury sustained during a seizure (falls, burns, cuts). Recurring injury reports inform discussions about activity restrictions, helmet use, driving prohibition review, and environmental modification.

Anti-seizure medication side effect tracking: Weekly symptom questionnaire captures fatigue, cognitive difficulties, mood changes, visual symptoms, and GI distress — the most common ASM side effects. Progressive side effect burden → provider review for dose adjustment or medication switch.

Menstrual cycle correlation (for women with catamenial epilepsy): female patients with perimenstrual seizure clustering may benefit from cycle-correlated data collection in the RTM platform, enabling identification of catamenial epilepsy pattern and consideration of progesterone or acetazolamide perimenstrual supplementation.

RTM Billing for Neurology: Code Selection and Documentation

Neurology RTM billing uses CPT 98975-98981, the same RTM code set used in other specialties. The specific codes applicable to neurology RTM are determined by what type of data is being monitored.

CPT 98975 — Device supply and initial education, billed once at enrollment. ~$19.

CPT 98977 — Monitoring of non-physiologic data (symptom tracking, medication adherence, functional status) — the relevant code for neurology RTM programs monitoring migraine frequency, MS symptoms, and seizure logs. Requires 16+ days of patient data transmission in the billing month. ~$48/month.

CPT 98980 — Treatment management, first 20 minutes of QHP or physician time reviewing RTM data and making clinical decisions. For neurology, this covers: reviewing migraine diary data and adjusting preventive therapy, reviewing MS symptom changes and coordinating urgent evaluation, reviewing seizure log data and adjusting ASM dosing. ~$50/month. Documentation required: specific data reviewed, clinical assessment, decision made or plan confirmed, time spent.

CPT 98981 — Additional 20 minutes of treatment management. ~$41/month. Applicable when a complex month (active MS relapse evaluation, seizure cluster management, migraine medication overuse intervention) requires extended provider review time.

Provider type for 98980/98981: must be a physician, NP, or PA — not a clinical staff member or MA. The physician or QHP must personally review the RTM data and make the clinical decision. A physician who delegates RTM data review to an MA without personally reviewing data cannot bill 98980.

Medical necessity documentation: the ordering physician's chart must contain: (1) the RTM order specifying what is being monitored and why; (2) the clinical rationale connecting the monitoring to the patient's diagnosis and treatment plan (e.g., "Enrolling patient in migraine RTM program to track monthly headache days for preventive therapy response assessment and CGRP biologic re-authorization support"); and (3) monthly provider review notes with specific data cited.

Revenue Math: 70 Neurology Patients on RTM

Building the revenue model for a neurology practice with 70 patients enrolled in RTM — a mix of 35 migraine, 20 MS, and 15 epilepsy patients — using 2025 Medicare national non-facility rates:

Monthly RTM subtotal: $7,655 / Annual: $91,860

For practices also billing CCM for eligible neurology patients (epilepsy patients with 2+ chronic conditions, MS patients with 2+ chronic conditions): - CPT 99490 (CCM, 20+ min clinical staff time): $62.00 × 35 dual-eligible patients = $2,170/month - CPT 99439 (add-on): $47.00 × 14 = $658/month

CCM additional monthly: $2,828 / Annual: $33,936

Combined RTM + CCM annual gross: $125,796 for the 70-patient program.

Program costs: RTM platform ($10-13/patient/month × 70 = $8,400-$10,920/year) + neurology RTM coordinator (0.25 FTE RN or LPN at $65,000 salary = $16,250/year). Net contribution: $98,876-$101,396/year.

Revenue per hour of provider RTM time: at 20 minutes per patient per month, 70 patients = 1,400 minutes (23.3 hours) of provider RTM review time per month. Monthly RTM revenue: $7,655 ÷ 23.3 hours = $329/hour — a competitive revenue per hour rate that compares favorably with outpatient neurology E/M visit rates (~$145-$210 per 20-minute visit = $435-$630/hour but without the RTM administrative overhead).

Note: many neurologists find that RTM data review can be batched efficiently — reviewing 15 migraine patient diaries in a focused 30-minute session at the end of the clinic day, rather than interrupting the visit schedule. This batching model makes the per-hour revenue calculation more favorable and less disruptive to clinical workflow.

Coordinating RTM with Neurology Office Visit Workflow

RTM data must be integrated into the neurology office visit workflow to fulfill its clinical potential. A neurologist who conducts RTM data review as an isolated between-visit activity but does not reference that data during office visits is creating parallel, disconnected clinical records — a compliance and quality risk.

Pre-visit RTM summary integration: the electronic visit pre-summary should auto-populate with the patient's RTM trends for the period since their last visit. For a migraine patient, this means: headache days per month for each of the past 3 months, acute medication days per month (MOH screening indicator), average severity, and flagged alert events with the clinical responses documented. The neurologist enters the room knowing the objective data, not waiting for the patient's self-report.

RTM data as the basis for billing higher-complexity E/M: when a neurologist reviews 90 days of migraine RTM data during a quarterly office visit, the complexity of medical decision-making is higher than a visit with no objective inter-visit data. This justifies coding the visit at 99215 (high complexity MDM or ≥40 minutes total time) rather than 99214. Document: "Reviewed patient's 90-day RTM migraine diary showing 14 headache days/month in month 1, 11 in month 2, 12 in month 3 — insufficient response to current preventive therapy; discussing CGRP monoclonal antibody initiation."

MS relapse response coordination: when an RTM alert indicates a potential MS relapse, the clinical response workflow may include: same-day phone assessment by the neurologist or NP, urgent MRI ordering (brain ± spine with contrast), neurology office visit within 3-5 days, and high-dose methylprednisolone initiation if relapse confirmed. Each of these activities generates billable clinical work — telehealth visit (99421-99423 for digital E/M), MRI order with AUC documentation, office visit, and infusion management.

Seizure cluster response protocol: a seizure cluster alert (3+ events in 24 hours) should trigger a same-day telephone consultation with the neurologist or NP. If cluster represents a change from baseline, consider rescue benzodiazepine (diazepam rectal gel, midazolam nasal spray, clonazepam dissolving tablet) instruction, same-day or next-day office evaluation, or ED direction if seizure activity is not resolving.

Building the Neurology RTM Program: Patient Selection and Launch

A neurology RTM program launch requires careful patient selection, a clear enrollment process, and a defined clinical response infrastructure before the first patient is enrolled. Practices that enroll patients before the infrastructure is in place create RTM alerts that are not acted upon — a compliance risk and a clinical quality problem.

Patient selection framework by condition: